Singapore, March 31 -- Matricelf, a biotechnology startup based in Israel developing a novel autologous engineered neural tissue therapy for patients with spinal cord injury, has entered into a Collaborative Research Agreement with the CiRA Foundation, a global leader in induced pluripotent stem cell (iPSC) research and regenerative medicine.

The collaboration represents a strategic step toward evaluating advanced manufacturing approaches that may enable scalable, efficient, and cost-effective production of regenerative therapies.

Under the agreement, Matricelf will assess the integration of iPSCs produced by the CiRA Foundation into its proprietary neural tissue engineering platform. The objective is to evaluate whether combining these...